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Abstract
Purpose of Review To give an overview of the evolvement of
transoral laser microsurgery (TLM) in the treatment of early
glottic carcinoma and highlight the contribution of recent
literature.
Recent Findings The indications and limits of TLM have
been well specified. Effects on swallowing have been well
documented. Introduction of narrow-band imaging (NBI)
and diffusion-weighted magnetic resonance has been shown
of additional value for outcome. The first reports on transoral
robotic surgery show that it may be of added value in the
future.
Summary TLM for early glottic carcinoma (Tis–T2) has very
good oncological outcomes with indications of higher larynx
preservation in TLM than that in radiotherapy. The anterior
commissure is a risk factor if involved in the cranio-caudal
plane, and reduced vocal fold mobility is a risk factor when
this is due to arytenoid involvement. The best voice results are
achieved when the anterior commissure can be left intact
along with part of the vocal fold muscle although even in
larger resections, patient self-reported voice handicap is still
limited.
Keywords Earlyglottic carcinoma .Earlyglottic cancer .Tis–
T1–T2 . TLM . Laser . Voice outcome
Introduction
Early glottic squamous cell carcinoma (Tis–T2) is a highly
treatable disease by any of the main treatment modalities
available. With total laryngectomy as ultimate salvage, it
carries a good prognosis for disease-specific survival regard-
less of the initial treatment strategy [1–5]. An important goal
of initial treatment, other than survival, is therefore functional
organ preservation by optimizing local control while avoiding
total laryngectomy. Secondary parameters such as functional
outcome (voice, swallowing, and airway), morbidity, and
quality of life also play a large role when choosing treatment
strategies, and in today’s healthcare systems, costs of treat-
ment must also be incorporated.
The two main treatment modalities for early glottic carci-
nomas (Tis–T2) are organ sparing surgery in the form of
transoral laser microsurgery (TLM) or open partial laryngec-
tomy (OPL) and radiotherapy (RT). They are all used both in
primary treatment and in the treatment of recurrent disease.
There is no formal proof that one treatment is more effective
than the other including a recent Cochrane analysis [2•, 4, 5]
although there is evidence that TLM as a primary treatment
modality is associated with a higher laryngeal preservation
rate than RT in early glottic carcinoma [6–9], and though it
was not randomized, the study by Mahler was well controlled
[6]. Therefore, treatment strategy depends on surgeon and
patient preference and varies between countries, institutions,
and individual surgeons. Advantages of TLM over alternative
modalities include shorter hospitalization, lower morbidity,
and superior functional outcomes compared to those of OPL
[10••, 11••] and shorter treatment time and less damage to
healthy tissue compared to those of RT. Also, an important
advantage of using TLM as a primary treatment strategy is that
it leaves open all treatment options in patients with recurrent
disease. This may explain the fact that the studies mentioned
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earlier have found lower laryngectomy rates in cohorts of
patients initially treated with TLM. TLM has also been shown
to be more cost-effective than OPL or RT [12–16]. Because of
the above-mentioned advantages, TLM has gained wide-
spread approval and has now replaced OPL as the primary
surgical modality. And although RT has traditionally been
the gold standard of treatment for Tis–T2 glottic carcinoma,
many clinics, especially in Northern Europe and the USA,
have now adopted TLM as the primary treatment modality
for early glottic carcinoma. This review focuses on the out-
come of TLM in current treatment of precancerous lesions and




TLM as a procedure was first introduced in 1972 by Strong
and Jako when they coupled a carbon dioxide laser to a sur-
gical microscope [17]. Although initially used by many to
treat small glottic lesions with reports showing high rates of
local control (90–94%) and low rates of laryngectomy (0–4%)
in selected midcord T1a carcinoma [14, 18–20], the technique
was also developed further in the 1980s and 1990s by Eckel
and Steiner among others. In his 1992 publication, Eckel re-
ports on 110 patients treated with TLM from 1986 onward of
which 80were glottic tumors (Tis 8, T1a 28, T1b 8, T2 31, and
T3 5). He also presented a classification system of resections
(type I–IV), which forms the basis of the classification system
used by the European Laryngological Society (ELS) today
[21]. In the following year, Steiner published a series of 159
patients treated with TLM between 1979 and 1985 (29 Tis, 96
T1, and 34 small T2 tumors with mobile vocal fold) in which
he reported a recurrence rate of 6% for this group and a
disease-specific survival of 100% [22]. These two reports
were the first to show that TLM could be used to safely re-
move larger lesions extending beyond the membranous true
vocal fold to other laryngeal structures such as the arytenoid,
anterior commissure, and the sub/supraglottis (T2–T3) laying
the basis for current concept of TLM in laryngeal cancer.
Concept of TLM, Oncological Outcomes, and Limitations
Contrary to open surgical procedures where the dissection
involves removing anatomical structures following standard
surgical routes, TLM is based on following the actual tumor
spread itself, resecting only the involved tissue and structures
using narrow margins to spare uninvolved structures and
therefore improve functional outcomes. In doing so, TLM as
a technique aims to remove the tumor by applying a
phonosurgical narrow cancer-free margins resection for early
glottic lesions (with optimization of functional vocal out-
comes) or through a more aggressive compartmental resection
potentially involving larger portions of the larynx in case of
intermediate or advanced disease [23, 24••]. The ELS classi-
fication system for TLM resections is most widely used today
taking into account both the depth and surface area of the
resection [25, 26]. Small, midcord tumors can be resected en
bloc. More extensive vocal fold lesions are usually removed
piecemeal where transection of the tumor allows for a more
adequate assessment of depth of involvement and for better
exposition and more access during removal of the tumor. It is
often advisable to resect (part of) the false vocal fold and/or
petiole of the epiglottis to improve exposure. The overwhelm-
ing majority of surgeons use the CO2 laser for TLM. Its wave-
length (10,600 nm) is absorbed by water, which allows for
both cutting and ablation modes. Vessels smaller than
0.5 mm are coagulated which regulate bleeding. With the
improvement in technical aspects such a scanner applications
and pulsed delivery of the laser beam, adverse tissue effects
have been reduced and precision increased in the past decades.
Following this concept, several large studies of consecutive
patients published between 2000 and 2010 have shown that
TLM provides excellent oncological outcomes with very high
disease-specific survival for all stages of early glottic carcino-
ma with local control and larynx preservation being the
highest in Tis and T1 tumors [27–31]. The outcomes of these
studies are summarized in Table 1 to give an impression of the
outcome that is achieved in large series with limited selection
bias where TLM is performed by experienced surgeons. In the
case of updated series from the same group, only the last series
has been included.
Outcomes of TLM in Recent Years
A number of additional larger reports (>100 patients) on on-
cologic outcomes in early glottic carcinoma have been pub-
lished since 2010 [33–38]. Most of them are in line with the
findings of the larger series mentioned earlier. In some studies,
outcomes are outside the ranges shown above, in these cases
mostly by a few percentage points. Larger variances are main-
ly seen in studies with <20 patients within a T categories, in
which one single aberrant case will shift outcome significantly
[39–41]. Aside from random variations due to small numbers,
positive deviances may also indicate selection bias with the
most favorable lesions being chosen for TLM whereas the
larger studies included in the table above tend to consist of
(near) consecutive patients. Therefore, it is hard to determine
the value of deviant findings. Incorporating all these studies in
a table such as the one above would lead to large ranges in
outcome making interpretation difficult or even meaningless.
Therefore, as stated above, the outcomes in Table 1 should be
viewed as what is attainable in large series of (near) consecu-
tive patients treated by experienced surgeons.
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Limitations of TLM
Current limitations for TLM resection of glottic lesions are
well summarized and discussed by Peretti in a recent paper
from 2016 [24••]. He points out that reasonably high rates of
success in terms of oncological and functional outcomes can
be achieved for superficial lesions of the entire larynx with
limited deep invasion towards the anterior and lateral visceral
compartments. Involvement of the posterior paraglottic space
with encroachment of the cricoarytenoid joint and infiltration
of the laryngeal framework negatively influence both onco-
logical and functional outcomes, and the role of TLM here is
limited to anecdotal cases. In the case of reduced vocal fold, its
mobility is therefore important to ascertain whether this is due
(only) to muscle infiltration and tumor bulk or if there is actual
fixation of the joint as these two entities carry a different
prognosis. For patients with lesions of the anterior commis-
sure extending to the supra- or sublgottis in the cranio-caudal
direction, there is a higher rate of local failure but in this case,
salvage therapy in the form of open surgery or non-surgical
treatment is not hampered by previous TLM. In another recent
and insightful review of TLM from 2015, Hartl points out that
a definite prerequisite for TLM is maintaining the cricoid car-
tilage as an unstable airway structure leads to laryngeal steno-
sis and permanent tracheotomy. Because of impossibility of
obtaining sufficient margins while maintaining a patent air-
way postoperatively, the need for cricoid cartilage resection
is a contra-indication for TLM. Also, at least one
cricoarytenoid unit (cricoid, arytenoid, cricoarytenoid joint/
muscles, and associated recurrent nerve) must be spared to
preserve laryngeal sphincter function. According to the au-
thor, it is generally accepted that prophylactic treatment of
the radiologically classified N0 neck is not necessary as the
rate of occult neck metastasis for early glottic cancer is less
than 10% [42].
Factors Affecting Oncological Outcomes of TLM
Although TLM is recognized as a standard treatment for Tis–
T2 glottic carcinoma, controversy still exists as to the predic-
tive factors for recurrence which may warrant revision after
TLM or treatment by an alternative or additional modality
[43]. Factors that have been identified as prognostic for a
poorer outcome are T category, vocal fold fixation, arytenoid
involvement, lateral extension into the bottom and roof of the
ventricle with or without false cord involvement, anterior
commissure (AC) involvement, and positive resection mar-
gins [40]. However, as Hoffman points out in a well-detailed
discussion on the subject, currently, clinical risk stratifications
for many of these factors remain inconsistent [43]. Some of
the most common risk factors are discussed below.
Definition of Early Glottic Carcinoma, and Tumor
Category and Subcategory
There is no clear clinical definition for early glottic carcinoma.
Some authors take it to include Tis and T1 lesions only, others
define it as also including limited T2 lesions with a mobile
vocal fold and an N0 neck, and others yet include all T2
lesions. Therefore, care has to be taken as to the specific
make-up of the population of a study when evaluating the
results.
Even with a fixed definition, there are still issues. As the
TNM classification for T1 tumors only considers superficial
spread and does not take into account the depth of a lesion,
patient populations can still be heterogeneous depending on
the individual interpretation of the TNM staging by the sur-
geon. Furthermore, as Ferlito points out along with DeSanto
and Olsen, not all T1 lesions will behave in a similar fashion.
Large T1 lesions may as a group behave more aggressively
and follow a course more reminiscent of a higher T2/T3 cat-
egory [44, 45]. This is illustrated by our own findings showing
that when favorable T1 lesions (superficial midcord) are se-
lectively treated with TLM, the outcome after RT for the re-
maining larger T1 lesions is less favorable than would be
expected for an entire group of T1 glottic carcinoma treated
with RT [46]. It is important to realize that also with the alter-
native treatment of RT, there is a subgroup of T1 glottic car-
cinomas that show a poorer response reminiscent of T2 le-
sions. This may be due to differences in biological behavior
but the lack of clear staging criteria for depth infiltration and
the resulting variation in staging between T1 and T2 tumors
may also contribute to this phenomenon. Early lesions on the
Table 1 Summary of outcomes
in large series of consecutive
patients [30–32]










Tis 70–94 94 99–100 100
T1a midcord 90–94 – 96–100 99–100
T1 85–87 93–95 94–98 99
T2 66–82 79–86 82–95 98
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free edge of the vocal fold have a tendency to remain confined
to the lamina propria, superficially involving the AC and/or
the vocal process of the arytenoid. Deep extension is limited
by the vocal ligament, which reduces the possibility of vocal
muscle infiltration [29]. In the author’s opinion, these lesions
are true T1 lesions rendering the favorable prognosis expected
of a T1 tumor. Any gross involvement of the vocal fold mus-
cle—regardless of normal mobility—should therefore be con-
sidered a T2 tumor necessitating larger resection margins and
more rigorous follow-up including imaging as the chance of a
submucosal recurrence is higher than that in superficial le-
sions. Care should be taken to assess depth of infiltration both
at the free edge and in the floor of the Morgagni sinus. As
there is no ligament present here, anything but superficial
involvement of the mucosa will involve the thyroarytenoid
muscle and should therefore be considered a T2 tumor.
Interestingly, in 2011, Lucioni published his results both ac-
cording to TNM classification and to ELS resection type,
which is more reflective of the true extent of the lesions.
Such a classification may ultimately be of additional value
in assessing prognosis in TLM of early glottic carcinoma
[41]. Despite of the above confounders, current TNM classi-
fication (Tis, T1, and T2) has been found to significantly affect
prognosis in TLM of early glottic carcinoma [28].
The same is true for the T1 subcategories T1a (localization
on one vocal fold) versus T1b (localization on both vocal
folds) as well as the discarded subclassification for T2 tumors
in T2a (normal mobility of vocal fold) and T2b (impaired
mobility of vocal fold) as a number of recent studies have
highlighted. Lucioni found a local control with primary laser
of 90% for T1a (n = 124) and 81% for T1b (n = 37). Ultimate
local control with laser alone was 98 and 90%, respectively,
and larynx preservation rate was 98% in both cases [41]. In
2015, Canis published the 27-year experience (1979–2006)
with an impressive 404 cases of T1a glottic carcinoma of the
Gottingen group. Local control was 86% and larynx preser-
vation was 97% with a disease-specific survival of 98% [47•].
A review of 16 studies on local control after TLM by O’Hara
published in 2013 confirms this rate of local control for T1a
(88%, n = 985) but finds that T1b tumors have a lower local
control rate, although the study population is also smaller
(78%, n = 187) [48]. As for T2 tumors, Canis again published
a very large cohort in 2014 detailing their experience with T2
glottic tumors treated between 1979 and 2006 divided into
142 T2a (mobile cord) and 127 T2b (fixed cord). The 5-year
local control was 76% for T2a tumors and 57% for T2b tu-
mors. Larynx preservation was 93% in T2a patients and 83%
in T2b patients with a disease-specific survival of 93 and 84%,
respectively [49•]. In conclusion, these numbers show that
there is a trend for lower local control within the T1 category
for T1b versus T1a as well as for lower local control, larynx
preservation, and disease-specific survival within the T2 cat-
egory in T2b patients compared to that in T2a. Although
officially the T2a and T2b subcategories are no more part of
the UICC or AJCC staging systems, it is important to realize
that impaired mobility of the vocal fold carries a poorer prog-
nosis in TLM. As stated earlier, this poorer prognosis seems to
be associated mainly with tumor infiltration of the posterior
paraglottic space resulting in fixation of the arytenoid joint
and not with impaired mobility from vocal fold muscle infil-
tration or pure tumor bulk. Peretti did not find an impact on
local control for the latter, and in making this important dis-
tinction, he argues that in these cases, a cordectomy extended
to the entire paraglottic compartment has been shown to be an
oncollogically safe procedure [29].
Anterior Commissure Involvement
Anterior commissure (AC) involvement has often been argued
to be a risk factor for recurrence because of the particular
anatomy of this region. In the past, some studies have found
it to be a risk factor for recurrent disease [50–53], and others
have not [29, 54–56]. Several recent studies have investigated
the anterior commissure as an independent risk factor for local
recurrence [43, 57–60]. Notably, in a large study from 2009
published by Rödel (463 T1–T2), analysis showed involve-
ment of the AC to be associated with decreased local control
in T1a and T1b but not in T2 tumors although survival was not
affected. The author argues that TLM is still an effective treat-
ment for tumors located in the AC as most of the recurrent
tumors could still be treated with further TLM procedures
[57]. Conversely, Hakeem found local control significantly
lower in T2 patients with AC involvement but not in T1a or
T1b, although there was a trend for poorer local control in T1b
tumors in his study of 296 T1–T2 patients [60]. Laryngeal
preservation rate and overall survival were not affected.
Hoffman found patients with AC involvement to have lower
local control, laryngeal preservation rate, and disease-specific
survival in her study of 201 patients with Tis–T2 glottic car-
cinoma [43].
The discrepancies found between studies may be due in part
to discrepancies in staging. Peretti highlights [24••] that it is
important to differentiate between tumors located in the AC in
the horizontal plane and tumors extending from the AC in the
vertical plane to the supra- and/or subglottis. At the level of the
true vocal folds, the thyroid cartilage is situated directly under-
neath the vocal folds which attach to the cartilage by Broyles’
ligament formed by the union of the thyroepiglottic ligament and
the attachment of the vocal ligaments and consisting of dense
fibroelastic tissue without glandular structures, blood, or lym-
phatic vessels [29]. Some authors argue this to be a weak point
where tumor easily penetrates the cartilage transforming a T1
tumor into a T4 [43, 61]. Conversely, others have emphasized
that Broyles’ ligament protects the cartilage and that therefore,
tumors with superficial extension in the AC, especially in the
horizontal plane (T1), rarely show thyroid cartilage infiltration
Curr Otorhinolaryngol Rep (2017) 5:56–68 59
[29, 62, 63]. This is in line with the author’s own experience
where a past inventory at our institution of T1 tumors with ante-
rior commissure involvement did not reveal any cases of hidden
cartilage invasion (unpublished data). Peretti argues that tumors
with pure horizontal spread in the AC form a good indication for
TLM. The risk of poorer local control arises from tumors with
vertical extension from the AC as these tumors have a close
relationship with the underlying visceral spaces (pre-epiglottic
space and subglottis) and carry a risk of microscopic spread into
these areas. In support of this reasoning in which he highlights
this important distinction, he found a negative impact on local
control only for those tumors crossing the anterior commissure in
the vertical plane [29]. Most authors agree that there is no abso-
lute contra-indication for TLM for transcommissural tumors in
the vertical plane although they emphasize that proper assess-
ment of tumor extent using 70-degree-angled endoscopes, thin-
slice (1 mm) CT, or MR imaging in anything but superficial
lesions as well as complete exposure of the operating field, wide
resection margins and advanced surgical skills are mandatory
when dealing with tumors in this anatomic location to avoid
understaging and possibly undertreatment [24••, 29, 58]. In a
detailed report on AC involvement in T2 lesions, Blanch empha-
sizes the importance of a wide excision in a horseshoe shapewith
a top-down approach which systematically includes the resection
of the base of the epiglottis, the ventricular folds, and some of the
inferior pre-epiglottic fat when dealing with these tumors in their
extensive report on AC involvement in T2 lesions. This superior
wide approach enables a better identification of depth of infiltra-
tion and facilitates subsequent fiberendoscopic control. Notably,
the author also found recurrence after TLM of the anterior com-
missure to be significantly related to the learning curve of the
surgeon [58]. The ELS type VI resection was introduced in 2007
in a revision of the original classification (type I–V) specifically
to deal with resections of the AC [26].
Resection Margins
In TLM of early glottic carcinoma, it is generally accepted that
a proportion of patients with positive margins will not develop
a recurrence, and the relationship between resection margin
status and relapse rate is still unclear. Difficulty in assessment
of pathological specimens is a particular problem in TLM
because of small sample size further compromised by carbon-
ization, retraction, and issues with orientation. Also, studies
on the role of resection margins in predicting recurrence after
TLM in early glottic carcinoma vary in their recommenda-
tions. At the glottic level, most authors consider 1–2 mm as
an adequate margin although some authors have suggested
that margins less than 0.5 mm may be enough in Tis–T1 car-
cinoma as the ligament still forms a barrier to tumor spread in
early lesions (Table 2). Although we accept very narrow mar-
gins in Tis–T1 lesions, the author believes that care should be
taken to realize margins at the higher end of the spectrum once
the tumor has spread beyond the ligament. In accordance with
this, Canis reported obtaining margins of 2–3 mm in T2 tumors
[49•]. Authors also differ in their handling of positive or inade-
quate margins. As shown in Table 3, four authors chose a com-
plete wait and see policy [64–67]. Others preferred await and see
attitude but performed several second-look procedures, on clini-
cal indication [68–70] or using the site of the positive margins
(deep versus superficial) to decidewhether a patient should be re-
excised or not [32]. Re-treatment with either TLM or radiother-
apy was standard only for three authors [71–73], although not all
patients were handled according to protocol, mainly because of
patients’ preference. As a result, there were two studies in which
positive/inadequate margins were handled with re-treatment in
the majority of cases [69, 72].
Table 3 represents the fraction of cases receiving re-
treatment in association with the total fraction of
recurrences.
The average recurrence rate reported by authors adopting a
wait and see attitude appears to result in a slightly higher
chance of recurrence (mean of 13.5%), as opposed to that of
those who choose the more aggressive approach of re-treating
most patients (mean of 9%). Despite this, it has been argued
that instead of solely assessing the surgical specimen, an ex-
perienced intra-operative opinion on how radical the surgery
was is deemed an important factor in decision-making.
Sigston advocated a “wait and see” policy, pointing out that
because of the readily accessible localization of glottic can-
cers, qualitative visual follow-up is adequate for monitoring
patients. Moreover, the glottic area generally reveals symp-
toms earlier than other areas, enabling earlier detection, as
patients will visit their physicians outside of protocol if they
experience symptoms [64]. Sigston and coworkers found that
84% of their patients with positive surgical margins would
potentially have received unnecessary additional treatment
without this wait and see policy [64]. Later authors have also
adopted this point of view [65, 66, 68, 69]. At the author’s
institution, we agree with this reasoning although we adopt a
more aggressive policy in positive deep margins, especially in
larger T1 and T2 tumors as the chance of a submucosal recur-
rence is larger in these cases. As for second-look
microlaryngoscopy, the recent ELS recommendations on
follow-up after treatment for laryngeal cancer take the position
that a second-look microlaryngoscopy is mandatory in case of
positive margins and can be indicated in various other situa-
tions such as close margins, granulomas, web formation, or
involvement of certain laryngeal subsites such as the AC, the
laryngeal ventricle, and the subglottis [74].
TLM in Salvage
TLM is used in the treatment of recurrent disease either after
initial TLM or after RT. However, the local control of salvage
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TLM is lower than that in primary surgery. Peretti found that
the pathway of spread in the recurrent carcinoma is the most
important factor in predicting its endoscopic curability. He
classified 58 patients according to the location of the recur-
rence compared to the initial site of the tumor. Salvage TLM
was possible in 86% of patients where the recurrence occurred
in the same area, and in 74% if the recurrence occurred in
adjacent sites with superficial spreading or multifocal
distribution. In the case of submucosal recurrence with spread
in the visceral spaces of the larynx or cartilaginous frame-
work, no patient was cured endoscopically [29]. Recently,
Rödel reported a 5-year local control and larynx preservation
rates of 64 and 91%, respectively, with repeated TLM in pa-
tients with early recurrence (rTis–rT2N0) initially treated for
early glottic carcinoma (pTis–T2). For advanced recurrence
(rT3/T4aN0/N+), these were 28 and 75%, respectively. The
authors conclude that in case of early local recurrence after
primary TLM for early glottic carcinoma, further TLM seems
to be justified as an organ-preserving treatment option. In
contrast, salvage laryngectomy should be considered early
for patients with advanced local or loco-regional recurrence
[75]. Huang analyzed 50 rT1–T2 lesions treated with salvage
TLM and found local control to be 70% with a larynx preser-
vation of 88% and disease-specific survival of 98%. A second
recurrence after salvage TLM significantly impacted larynx
preservation and disease-specific survival causing the author
to argue for oncological safe resection margins in salvage
TLM rather than sparing healthy tissue for a good voice out-
come [76].
Table 2 Studies on margin status























52 >0.5 35 100%: FU
Tis–T2 Ansarin (2009)
[72]










110 NA 24 100%: FU
Tis–T3 Peretti (2010)
[28]













171 >1–2 36 100%: FU
T1–T2 Fang (2013)
[67]
75 >1–2 51 100%: FU
Crespo (2006)
[71]
40 NA 20 25%: RT
75%: FU
Table 3 Table 3 Fraction of cases in literature receiving re-treatment
and having a positive or inadequate surgical margins after TLM for early
glottic carcinomas and the association with recurrence rates and mean
recurrence rates
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Recent Advances in TLM-Related Areas
Optical and Molecular Imaging Techniques
To improve tumor detection and tumor margin identifi-
cation, a number of optical and molecular examining
technologies have been developed over the last few
years. These technologies can be divided in those that
improve superficial detection of tumor extent in the su-
perficial plane such as fluorescent imaging, contact en-
doscopy, and narrow-band imaging and those that aim
at detecting extension in the deep plane such as optical
coherence tomography, confocal endomicroscopy, and
Raman spectroscopy. One of the most implemented
techniques in clinical practice so far is narrow-band im-
aging (NBI). This is an endoscopic technique that uses
selected wavelengths of light to enhance the vascular
pattern of the mucosa. Superficial carcinomas are better
identified due to their aberrant vascular pattern. This
technique has been shown to increase diagnostic accu-
racy in terms of better definition of surgical margins,
tumor staging, and early detection of residual or recur-
rent disease as compared to ordinary white light endos-
copy [77]. Piazza found that 18% of patients had a
diagnostic gain by using NBI compared to routine white
light endoscopy [78]. Bertino found a diagnostic gain of
11% in terms of margin definition and 18% in terms of
suspicion of malignancy [79]. Kraft found accuracy to
increase from 90 to 97% when using NBI as opposed to
routine white light endoscopy [80]. Finally, Garofolo
found that when using NBI to guide resection margins,
the rate of positive superficial margins was 3.6% as
opposed to 23.7% in a control group [81]. The diagnos-
tic advantage afforded by NBI has also been shown to
apply after radiation and/or chemotherapy [82, 83]. In
their recommendations for the follow-up of laryngeal
cancer, the ELS recently stated that incorporating NBI
into postoperative surveillance will give more accurate
follow-up [74]. Despite these advances in diagnosing
superficial extension of early glottic lesions, the chal-
lenge of depth resolution still remains, and there is as
of yet no routine clinical application to guide the depth
of TLM resection in the upper layers of the vocal fold
in superficial lesions. Technologies such as optical co-
herence tomography, confocal endomicroscopy, and
Raman spectroscopy are being developed but have not
yet been introduced in daily clinical practice. Routine
imaging (CT and MR) is invaluable in assessing tumor
involvement of deep structures such as the paraglottic
and pre-epiglottic spaces, laryngeal framework, and ex-
tra laryngeal soft tissues but are as of yet not detailed
enough to guide narrow-margin surgery of the lamina
propria and superficial vocal fold muscle.
Conventional Imaging Techniques (CT/MR)
Accurate clinical staging of early glottis carcinoma is critical to
therapeutic planning and for choosing between organ preserva-
tion strategies. Involvement of the visceral spaces of the larynx
(paraglottic and pre-epiglottic spaces) and laryngeal cartilage
framework must be ascertained to differentiate early glottic tu-
mors—particularly T2 lesions from more advanced categories
(T3–T4). Also, during follow-up, although superficial recur-
rences can be detected by endoscopy, submucosal recurrences
which are frequently observed after TLM [24••] are more diffi-
cult to detect and may spread within the deep visceral spaces of
the larynx before they are bulky enough to be detected by en-
doscopy. So in both diagnosis and follow-up, imaging plays a
crucial role in all but superficial T1 lesions. In the work-up of
laryngeal cancer, CT is currently the mainstay in the assessment
of submucosal tumor spread. However, MR has recently been
shown to bemore accurate in staging of T1–T2 glottic carcinoma
(MR 80% accurate versus CT 70%) [84]. Moreover, new MR
techniques such as diffusion-weightedMRhave also been shown
to offer a more precise definition of signals differentiating tumor,
edema, and scar. When clinical strategy depends on the precise
local mapping of primary or relapsing tumor (such as in ascer-
taining the indication for TLM), MR can provide information
that is presently beyond the capability of CT [85•] although
evaluation of MR needs a higher level of experience and inter-
disciplinary collaboration [84].
Alternative Laser Types
In recent years, alternative lasers have been introduced to treat
early glottic carcinoma. Using different wavelengths affecting
different chromophores of the tissue than the standard CO2 laser,
their main advantage is increased preservation of the vocal fold
soft tissue including mucosal superior lamina propria (SLP) in
more superficial tumors leading to superior functional (voice)
outcomes and shorter wound healing times. Also, most of them
do not require straight beam delivery and are used as flexible
fibers. In 2013, Murono obtained local control in 22 out of 24
patients with T1 glottic carcinoma treated with potassium-
titanyl-phosphate laser (KTP). In 2014, Zeitels published his
series of 117 patients (T1–T2) treated with KTP laser. Local
control for T1 and T2 lesions was 96 and 80%, respectively.
Fifty percent of recurrences were controlled with RT while the
other 50% failed RT and died of their disease. Disease-specific
survival was 99% for T1 and 89% for T2 [86]. This shows that
at least in T1 carcinoma, KTP may be a valid alternative to
traditional CO2 laser. The disease-specific survival in T2 is low-
er than that expected with CO2 laser. In 2014, Cömert showed
that diode laser was as effective in treating 72 patients with T1–
T2 glottic carcinoma as RT (local control diode laser 93% versus
RT 90%) [87].
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Transoral Robotic Surgery
Recently, transoral robotic surgery (TORS) has emerged as
an innovative technique in the surgical treatment of head
and neck cancer. For this technique, an angled vision en-
doscopic camera is introduced transorally through a mouth
gag to provide a magnified view of the pharyngo-laryngeal
structures. The surgery is performed with instruments that
allow scaled and tremor-filtered movement. This technique
results in wide tissue exposure that facilitates multiplanar
dissection. Additionally, natural hand tremor is filtered out,
large hand movements are adjusted, and the surgeon is
given true depth perception by the 3D visualization of the
surgical field [88•, 89]. Previous studies have demonstrat-
ed the value of this technique for other sites of the upper
aerodigestive tracts but the role of TORS among the dif-
ferent treatment options for early glottic cancer is still not
clear as the technique was not initially developed for this
application [88•]. Recently, it has been shown that combin-
ing TORS with CO2 laser fiber is feasible allowing for
precise cutting with a flexible tip and effective hemostasis
of vessels 0.5 mm or less [89]. Also, a preliminary study of
the feasibility of TORS in T1–T2 carcinoma of the glottic
and supraglottic larynx has been published [88•]. This
study which is the first report on TORS in T1–T2 glottic
carcinoma showed that although TORS is made difficult by
the same limitations as TLM (short neck, prominent inci-
sors, large tongue base, reduced mouth opening, and
retrognathism), it is not necessary to get a direct vision of
the laryngeal tumor in order to carry out surgery. In this
study, it was possible to access two carcinomas of the an-
terior commissure that were not approachable by TLM.
This may prove to be an added value of TORS to the
current treatment options in early glottic carcinoma.
Currently, the expectation is that in the coming years,
TORS will be adapted to better suit endolaryngeal surgery
with better exposure and finer instruments (Remacle, per-
sonal communication).
Functional Outcomes of TLM
When looking at functional outcomes, the three main func-
tions of the larynx potentially affected by any treatment are
airway, swallowing, and voice. Of these, vocal function is the
most frequently affected. Additionally, other acute or chronic
complications induced by the operation as well as overall
quality of life need to be considered.
Voice
Many studies have demonstrated that the quality of voice
after TML is related to the extent of the resection [90].
The general consensus in literature, as well as in the au-
thor’s own experience, is that type I–III resections, where
at least some of the vocal muscle and the contralateral
side of the anterior commissure are preserved, result in
very acceptable voices with only mild dysphonia and
low voice handicap reported by patients themselves
[91–93]. Grades of dysphonia for these resections vary
from less than 1 to 1.5 on the GRBAS scale (grade rough-
ness breathiness asthenia strain) for perceptual rating cor-
responding to mild dysphonia [91, 94–96]. Voice handi-
cap index (VHI) scores are very close to normal ranging
from 19 to 28 where 120 is the maximal score and scores
of 15 or under are considered normal [90, 92, 97]. Some
reports on voice outcomes after type I–II resections do not
even differ from normal controls [94, 95]. Conversely,
Vilaseca found that on average, voice quality after TLM
was worse than that in normal controls for every resection
type but that in the case of type I resection, perceptual
analysis showed it was normal in a majority (66%) of
patients and as high as 55% even in type III resections
[96].
However, wider excisions (type IV–VI) including total
resection of the vocal fold muscle and/or the AC will lead
to more severe forms of dysphonia in most patients.
Perceptual grades of dysphonia reported in these groups
vary from 1.6 to 2.7 [94–96, 98, 99] with most groups
reporting scores of 2 or higher meaning moderate to se-
vere dysphonia. The VHI in these patients is higher than
that in more superficial resections but still relatively low
ranging from 24 to 39 [90, 92, 98]. This relatively low
score indicates that patients seem to accept their voice
limitations. This is further supported by the fact that only
7% of 145 patients (T1–T4) were motivated for vocal fold
reconstruction after TLM. Even in a subgroup of extended
resections (type IV–V), this was only 16% [100]. Patients
that do undergo reconstruction can expect improvement
but not normalization of voice. Piazza reported a decrease
in the VHI from 46 to 21 [101] and Remacle from 65 to
33 [100] in their reconstructed patients.
The data on vocal outcome from the past few years
support earlier findings. Bahannan found that type I–III
resections result in a significantly better voice outcome
than type IV and V resections in 62 patients with Tis–T2
lesions. Fink reported a similar outcome in 49 patients
with Tis–T1a lesions. Patients undergoing type I–III re-
sections experienced on average an improvement in the
VHI from 39 to 23 whereas patients undergoing a more
extended resection had an increase in the VHI from 33 to
39 [92]. Mendelsohn found a postoperative VHI of 24 in
13 patients undergoing extended resections (type III–VI)
with a mean grade of 2 (moderate dysphonia) [102]. The
same author also published one of the only reports spe-
cifically on voice outcome after resections of the AC
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which showed a VHI of 37 and a mean grade of 2.1
(moderate dysphonia) in these patients [63]. Peretti report-
ed on 89 type V resections (59 T2 and 30 T3 carcinomas).
Voice outcome evaluation in a subsection of 48 of these
patients 1 year after surgery revealed VHI to be 20, and
perceptual dysphonia was mild in 82% and moderate in
18% of patients evaluated by the GRBAS scale [11••].
Additionally, two series looking at longitudinal out-
comes highlight the fact that voice shows an initial de-
cline after surgery but will improve [102, 103] and sta-
bilize at 6 months after TLM [103].
Interestingly, in a publication from 2013, Hillel chal-
lenges the accepted correlation between resection depth
and voice outcomes by raising the issue that patients un-
dergoing type II resection may even have better voice
outcome than those after type I resection, and that even
thought the ligament could be spared, it should be
resected in patients with only a minimal residue of SLP
for functional reasons [104•]. A computer model pub-
lished by Mau in 2015 provides theoretical support for
this finding although the authors state that further clinical
data are required to support this conclusion [105•].
Swallowing
As for swallowing, there is a dearth of data for limited lesions.
This may be because swallowing is an underestimated issue in
these patients but it may also point to the fact that it is not
considered an issue in clinical practice. In extended lesions,
sporadic cases of severe long-term dysphagia are reported. In
2004, Bernal-Sprekelsen published a series of 45 T2 glottic
carcinomas treated with TLM. The average duration of naso-
gastric feeding tube dependence was 0.18 days. Out of his 45
patients, only 1 underwent percutaneous endoscopic
gastrostomy placement, tracheotomy, and finally, total laryn-
gectomy for swallowing problems [106]. Two recent publica-
tions have contributed to detailing of swallowing after TLM.
In a series of 89 type V resections, Peretti found favorable
swallowing outcomes. In the MDADI (M.D. Anderson dys-
phagia inventory), self-evaluation questionnaire of
swallowing patients scored an average of 96 out of a maxi-
mum of 100. Only 2 and 4% of patients showed tracheal
aspiration on VEES (video endoscopic evaluation of
swallowing) and VFS (videofluoroscopy) examinations
[11••]. Age and T category were not found to impact these
results in a second prospective study of swallowing outcomes
in 40 patients with T2 carcinoma undergoing a type V resec-
tion, and Nasef found that only 12.5% of patients needed a
nasogastric feeding tube which was removed after less than
5 days in most cases. The mean MDADI score after 3 months
was 96, and none of the patients had incomplete laryngeal
closure compared to 40% at day 1 after TLM. The mean
duration of aspiration was 3.4 days [10••]. One important
point to make is that pulmonary function in patients undergo-
ing large resections, especially in recurrent tumors after RT
where laryngeal functions may already be compromised,
needs to be sufficient to withstand a period of aspiration be-
fore the sphincter function of the larynx is restored to avoid
pneumonia.
Airway and Other Complications
The upper airway and other complications are rare after
TLM. The large series described under the oncological
outcomes section reported the following complications:
in 719 patients, Motta reported subcutaneous emphysema
from penetration of the cricothyroid membrane in 5% of
patients, which necessitated tracheotomy in four. An ad-
ditional four patients required tracheotomy from oedema
after cauterization bringing the total amount of tracheoto-
mies to 1%. Bleeding resolved by endoscopic revision
occurred in 1.6% of patients. In 595 patients, Peretti re-
ported only major bleeding as a complication in 0.4% of
patients in which endoscopic revision was sufficient to
solve the problem. In 285 patients, Eckel reported one
patient who developed a glottic stenosis and required fur-
ther open surgery to restore an adequate airway. No other
complications were seen.
General Quality of Life
Quality of life (QoL) after TLM for early glottic carcino-
ma is generally good and does not differ significantly
from normal controls. Recently, Vilaseca published two
detailed studies on QoL in TLM. She found that 94% of
401 consecutive disease-free patients treated with TLM
(including 254 T1–T2 glottic carcinomas) evaluated 1 year
after treatment had a good QoL. RT and neck dissection
had a negative impact on QoL whereas old age had a
positive impact suggesting that older patients cope better
with their disease. Relative voice impairment was detect-
ed especially in locally advanced tumor, and T classifica-
tion (local early versus local advanced) and age were in-
dependent negative prognostic factors for QoL within the
speech domain [107•]. In an earlier publication by the
same author, 46% of patients considered speech as a rel-
evant issue in QoL while only 31% scored under refer-
ence values. The author theorizes that the high expecta-
tions of minimal invasiveness created by TLM and the
considerable percentage of patients that continue working
without any official recognition of their disability may
explain this discrepancy [108]. A third publication by
Vals-Mateus shows that scores on voice and swallowing
domains remain consistent over time and do not deterio-
rate [109•].
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Conclusion
TLM for early glottic carcinoma (Tis–T2) has very good on-
cological outcomes equal to those offered by other treatment
options (OPL and RT) with some evidence that larynx preser-
vation is higher in patients where TLM is employed as a
primary treatment strategy as opposed to RT. Additional ben-
efits of TLM are short treatment times, low morbidity and
complication rates, and lower cost. T subcategories (T1a/b
and T2a/b) have an impact on local control. Reduced mobility
(T2b) only has an impact on local control if this is due to
involvement of the arytenoid cartilage and not when this is
caused by vocal fold muscle infiltration or tumor bulk.
Involvement of the AC in the horizontal plane (T1) is not a
risk factor for local recurrence whereas involvement in the
vertical plane (T2) is. Voice outcome is near normal in limited
lesions, and although dysphonia is moderate to severe in larg-
er resections, patient-reported voice handicap is still limited.
The best voice results are achieved when the AC can be left
intact along with part of the vocal fold muscle. However, even
after extensive resections, only a minority of patients will wish
to undergo reconstructive phonosurgery, which can improve
voice outcomes significantly. Swallowing is very rarely affect-
ed in the long-term even in extensive resections. TLM has a
definite role as salvage treatment in early recurrent lesions
both after initial TLM and RT, and with careful patient selec-
tion, ultimate disease survival is not compromised by salvage
TLM. Introduction of NBI as an additional imaging modality
into diagnosis, treatment, and follow-up has significantly im-
proved disease detection and radicality of resections in the
mucosal plane. There may be an additional role for TORS in
the future in tumors that cannot be exposed by routine TLM
and lasers such as KTP and diode as alternatives to traditional
CO2 laser may have a role in sparing function if equal disease
control can be maintained which seems to be the case in initial
studies concerning T1 lesions.
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